therapy, who have left ventricular ejection fraction (LVEF) ≤35% and left bundle branch block (LBBB) with QRS width ≥120 ms. Little is known about the CRT use and outcomes of these patients in New Zealand. Our study aimed to examine the trends of CRT use in eligible HF patients living in the Northern Region of New Zealand and their outcomes. (Table 1) . 11 All referrals for CRT were discussed by the Northern Region implanting electro- 
| ME THODS
This
Clinical Record Information System (CRIS). Data collected via notes
review included patient demographic data, procedure-related data, acute (within 24 hours of implant), early (>24 hours to 2 weeks after implant) and late (≥2 weeks after device implantation) complications.
Hospitalization events were identified using the administrative data of MoH and NMDS inpatient hospitalization data via National
Health Index (NHI) number linkage up to December 2015. The NHI number is a unique identifier that is assigned to every person who uses health and disability support services in New Zealand. HF hospitalization was defined using the International Classification of Diseases diagnosis 10 (ICD-10) codes (I110, I130, I132, I500, I501, and I509).
Mortality data were collected using New Zealand mortality collection and NMDS. These include all registered deaths not just in- • EF ≤35% after ≥6 wk of optimal heart failure treatment, with QRS duration is >149 ms or is 120-149 ms with 2 additional criteria for dyssynchrony (aortic pre-ejection delay >140 ms, interventricular mechanical delay >40 ms or delayed activation of the posterolateral left ventricular wall) • NYHA class III • No major cardiovascular event in the prior 6 wk and be in sinus rhythm • No major comorbidity reducing survival <18 mo or seriously impairing quality of life ACE, angiotensin converting enzyme; EF, ejection fraction; ICD, implantable cardioverter-defibrillator; ICM, ischemic cardiomyopathy; MI, myocardial infarction; NICM, Non-ischemic cardiomyopathy; NYHA, New York Heart Association.
| Statistical analysis
Baseline characteristics were summarized as either mean with standard deviation (SD), median with interquartile range (IQR) or frequency with percentage depending on the nature of the data.
Comparisons between CRT-P and CRT-D were conducted using either the Wilcoxon rank-sum test, the chi-squared test or the two-sample Z test. Survival rates over time were depicted in KaplanMeier curves and the differences between survival distributions were evaluated with the log-rank test. Statistical analyses were performed using the statistical package SAS version 9.3 (SAS Institute, Cary, NC). All P-values resulted from two-sided tests and a P-value of <0.05 was considered statistically significant. In the CRT-P group, left ventricular lead placement was successful at initial implant in 41 patients (95.3%) and one patient required a second procedure which failed and required epicardial lead placement. Thirty-two (74.4%) were upgrades from pacemakers to CRT-P.
| RE SULTS
One patient did not receive the intended CRT-P device because of failed left ventricular lead placement.
| Context of Northern Region in CRT implantation
In the Northern Region, the number of individuals admitted with a diagnosis of HF was increasing year-by-year ( Figure 1 ). In a Swedish Heart Failure Registry, QRS prolongation with LBBB morphology ≥120 ms was present in 31% of patients with HF.
12 If ~30%
of patients each year with HF have underlying LBBB and systolic dysfunction, then the number of patients to be considered for CRTsupport in the Northern Region should also increase proportionally.
However, throughout the study period, the number of CRT implanted remained low ( Figure 2 ). There were differences in CRT-D and CRT-P utilization ( Figure 2 ). The percentage of CRT-D utilization gradually increased from 2007 to mid-2015. However, the utilization of CRT-P remained static during these times. Table 2 
Shown in

| Complications
There was a total of 26 complications between the groups (12.7%
in CRT-D group vs 13.9% in CRT-P group, P = 0.83) ( Table 3) . During the first 24-hour after device implantation, there were 11 perioperative complications (5.7% in CRT-D vs 4.7% CRT-P, P = 0.78). There was no difference in the occurrence of early and late complications (Table 3) . 
| Mortality
| Device therapy
Among the 157 CRT-D patients, 34 (21.7%) had device therapy 
| D ISCUSS I ON
This study describes the trends in CRT therapy use for eligible HF patients in New Zealand. We have observed a gradual increase in CRT-D implantation across the study period, with an increase in the proportion of patients receiving these devices for primary pre- in 2010. 15 By contrast, other European countries are still implanting a significant number of CRT-P: 39% in France, 44% in Sweden, 46% in Belgium in 2013. 16 The regional differences in implant rates most likely reflect the differences in health care system and the reimbursement situations.
TA B L E 2 Baseline characteristics of patients who received CRT-P and CRT-D
CRT-D (n = 157) CRT-P (n = 43) P-value
Mean age (y ± SD) 61. Affordability and capacity are of concern in this region. Despite the increasing number of HF patients year-by-year, only a small proportion of patients received these devices (Figures 1 and 2 ). 
TA B L E 3 Complications among CRT-D and CRT-P patients
F I G U R E 3 Kaplan-Meier survival curve of all-cause mortality in CRT-D and CRT-P patients. CRT-D, cardiac resynchronization therapy-defibrillator; CRT-P, cardiac resynchronization therapypacemaker ranging from 38.8% of eligible patients receiving CRT-P to 84.1% of eligible patients receiving CRT-D. 13 Considering current workforce, funding constraints and the conservative approach taken, the published 2010 New Zealand guidelines (Table 1) exists with unequal geographic distribution of echo services. 22 The reasons are likely multifactorial and contributed to by DHB demographic differences in age, ethnicity, and socioeconomic deprivation status as well as the size and demographics of the cardiac sonographer workforce. 22 In our study, echocardiographic assessments and cardiac MRI were the most commonly used measures, with all patients requiring LVEF to be quantified prior to discussion regarding clinical care with device support. LVEF is one of the most commonly reported measures of left ventricular systolic function. LVEF can be determined using several invasive and noninvasive imaging modalities, either subjectively by visual estimation or objectively by quantitative methods. 23 Currently, there is no universally accepted "gold standard" for measuring LVEF. Each method has limitations and potential for error. 23 Many factors should be taken into account when deciding which method is the most appropriate for an individual patient. The different ways to assess LVEF is beyond the scope of the current study because our study aimed to review the utilization and outcomes of CRT patients in the Northern Region of New Zealand.
In our study, 29 (14.5%) patients (14.7% in CRT-D vs 13.9% in CRT-P, P = 0.91) had died at the end of follow-up. The total mortality was relatively low compared to the published Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial (15%) and the CArdiac REsynchronizationHeart Failure (CARE-HF) trial (20%). 6, 7 One explanation is the younger population in our study. The mean age of our patients was 62.4 years vs 67 years in both COMPANION and CARE-HF. 6,7 Even though our CRT-P patients was older compared to the CRT-D patients, they were still relatively younger (mean age of 64.9 years) when compared to CARE-HF where only the impact of CRT-P was assessed. 6 This is likely due to the more conservative New Zealand guidelines for ICD and CRT-D in patients with HF compared to the International guidelines. 24 Another potential factor contributing to During the longer follow-up period in our study, 27.6% deaths were a result of progressive HF. This suggests that despite a more conservative approach, there was no survival penalty for those undergoing CRT-P rather than CRT-D support in our study. The mode of death in the COMPANION trial was most commonly pump failure (44.4%) even though both CRT-D and CRT-P modestly reduced mortality. 35 The CARE-HF trial confirmed that progressive HF deaths remained the leading cause of death in HF populations. 6 Current international guidelines give the same level of recommendation for CRT-P and CRT-D use. 33, 36 No clear preference is given to any treatment modality compared with the other. Prescription of these costly and complex devices should be preferentially for patients in need of secondary prevention or for the purpose of primary prevention in younger patients without major comorbidities.
Despite the low implant numbers, our perioperative and late complication rates are comparable to published data. 37, 38 There is cumulative evidence that implanting CRT-D devices is associated with a higher perioperative and postoperative risk of major complications compared with CRT-P. Romeyer-Bouchard et al reported an increased risk of infection with CRT-D devices compared with CRT-P. 37, 39 Another Danish study showed that the incremental risk of perioperative or 6-month postoperative complications was 1.5
(0.9-2.3) (P = 0.11) for CRT-P and 2.6 (1.9-3.4) (P < 0.001) for CRT-D compared with conventional pacemakers. 37 However, in our study there were no differences in perioperative and late complication rates between the two groups. This may be explained by the small number of CRT-P included in the study, and therefore no conclusive differences in complications could be drawn.
| Limitations
Our study is a retrospective study with prospective follow-up. The Our study does not represent the entire New Zealand. The four DHBs in Northern Region serve 38% of the total New Zealand population. 10 The implant numbers and the practice will be different from other implanting centers in the country.
The main strength of our study was long duration of follow-up (total duration of 10.2 years), accepting the limitation of a small cohort size. Uniquely we were able to classify the mode of death in 99.5% patients and able to capture all deaths rather than just inhospital death. Only one patient had an unspecified cause of death in the community. We were also able to capture all the hospitalization events in detail for patients. Furthermore, our study measured the outcomes including mortality and hospitalizations after implant, which is important when making decisions about the appropriate device choice for individual HF management.
| CON CLUS ION
There has been a steady increase in CRT implantation over time in the Northern Region of New Zealand. While the optimal per population implantation rate is speculative, these data suggest that there is a significant unmet clinical need for CRT implantation in the Northern Region. The reasons for low implantation of CRT devices require further examination.
